development strategy focuses on topical and oral treatment approaches in areas of significant medical and commercial importance, including several androgen related diseases and different forms of cancer. Each of ASC's therapeutic platforms demonstrate diverse medical applications, with lead compounds advanced in parallel for the treatment of pathologically related yet distinct clinical indications.

Both of ASC’s two therapeutic platforms are first-in-class MOA small molecules which selectively and potently inhibit aberrant or excessive levels of transcription factors activation. An expanding pipeline of drug candidates is based on Androgen Receptor Degradation (ARD) Enhancers and selective STAT inhibitors. ARD Enhancers display remarkable treatment potential in: Acne (phase IIb), Alopecia (phase I/II), with preclinical stage proof of concept in Prostate Cancer, SBMA (Kennedy’s Disease), HBV induced HCC, Bladder Cancer, and Wound Healing. STAT inhibitor compounds possess efficacy against a wide range of aggressive solid and hematological cancers and are undergoing preclinical development and final lead identification.